Merck MRK announced today that it has signed a new non-exclusive agreement with Roche, through the companies' respective subsidiaries,
for the global promotion, upon appropriate marketing approvals, of VICTRELIS as part of a triple combination therapy regimen with
peginterferon alfa and ribavirin.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in